Zhong Ji Longevity Science Group Limited (Stock Code: 767) issued a supplemental announcement related to its annual report for the year ended 31 December 2024. The disclosure focuses on the use of net proceeds from a prior subscription, details about share options, and clarifications on share award schemes.

The announcement states that net proceeds from the subscription totaled approximately HK$19.4 million. Of this amount, 60% was allocated to the expansion of the existing longevity science business and the new biomedical products trading business, while the remaining 40% was used for general working capital expenses such as staff costs, rental expenses, and related professional fees. All proceeds have been fully utilized.

According to the supplemental announcement, no share options were granted under the 2022 Share Option Scheme during the reporting period. Similarly, no restricted shares have been issued under the Share Award Scheme. As of both 1 January 2024 and 31 December 2024, the total number of shares available for grant under these share schemes was reported at 38,701,026 shares. The announcement also clarifies that the number of shares that may be issued in respect of options and awards granted during the period was nil instead of 16.02%.

The company emphasized that these supplemental details do not affect other information contained in the 2024 Annual Report.